Rayner
James Crutchlow has a diverse work experience spanning over 15 years in the pharmaceutical industry. James began their career at Pfizer as a Medical Representative for Wyeth Pharmaceuticals, a role they held from November 2006 to June 2008.
In 2008, James joined Rayner where they have taken on various roles of increasing responsibility. James started as a Territory Manager for the North of England from December 2008 to December 2010. James then moved on to become a Territory Manager for the North West from January 2011 to December 2011.
James transitioned into international roles within Rayner and served as an International Product Specialist from January 2012 to September 2012. James then became an International Business Manager for Northern Europe from September 2012 to November 2014. Following that, they took on the role of an International Business Manager for Europe & LatAm from November 2014 to December 2015.
In January 2016, James was appointed as the General Manager for Italy & Iberia, a position they held until September 2017. James then took on the responsibility of being the Director for North America from September 2017 to December 2019.
James most recent roles at Rayner include being the VP Direct Markets from December 2019 to January 2021, and currently serving as the VP Europe from January 2021 to the present.
Overall, James has demonstrated consistent growth and progression throughout their career, with a focus on international markets and leadership positions.
James Crutchlow completed their Bachelor's Degree from the University of Central Lancashire between 1997 and 2000. James then pursued a Master of Business Administration (MBA) from the University of Warwick - Warwick Business School, graduating between 2014 and 2017. No specific field of study was provided for either degree.
This person is not in any offices
Rayner
5 followers
Rayner designs and manufactures intraocular lenses and proprietary injection devices for use in cataract surgery. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention.With more than 65 years of continuous growth and experience, we remain at the forefront of innovation. Weare focused on providing the best IOLs for clinicians and patients and are driven by science to improve patient outcomes and safety.Primary IOLs Our FDA-approved C-flex aspheric (aberration-neutral) monofocal IOL, as well as our toric and multifocal IOL families are now complemented by the RayOne fully preloaded monofocal IOL injection system. Supplementary IOLsDesigned to be implanted in the ciliary sulcus, Rayner Sulcoflex Pseudophakic Supplementary IOLs are available as aspheric, toric, multifocal and multifocal lenses, and offer a reversible solution for correcting residual post-operative refractive errors following the implantation of a conventional IOL in the capsular bag.OVDsOur Ophteis range offers a full spectrum of OVDs from dispersive to cohesive, enabling surgeons to select the OVD best suited to each specific cataract procedure. Ophteis FR Pro with sorbitol -- designed to deliver a new level of corneal endothelial protection from phaco induced trauma -- is the flagship product of Rayner’s ‘Ophteis’ OVD suite. PharmaceuticalsAlthough the intraocular lens plays a leading role in the visual outcomes of cataract and refractive surgery, the pharmaceuticals that manage the tear film and inflammation are critical to the end result. For that reason, Rayner recently acquired the business of Moorfields Pharmaceuticals. The acquisition will enable us to offer an even wider range of ophthalmic tools that aid and streamline the surgical process whilst remaining focused on the visual outcome for the patient.Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 80 countries with direct markets in UK, Germany & Austria, the United States of America, Italy and Spain. We have the world’s longest commercial history of IOL design and manufacturing and have worked with cataract surgeons for longer than anyone else.In 2016, Rayner transferred its global headquarters to a brand new state of the art manufacturing plant, which has dramatically increased the company’s production capacity.